Clinical Trial Update: WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating MTX-463 for Idiopathic Pulmonary Fibrosis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• MTX-463

Snippet

Sponsor: Mediar Therapeutics | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: RECRUITING